Gapping down
In reaction to disappointing earnings/guidance: CCUR -30.4% BIOS -16.5%, ESLR -9.4%, MSPD -7.3% (also downgraded to Hold from Buy at Needham), ROG -6.5%, ENR -5.9% (light volume), , ADM -5.0%, HK -4.5%, VMC -4.1%, SANM -3.7% (also downgraded to Hold at Collins Stewart), THC -3.5%, CLX -3.3%, LYG -2.1%, EMR -2.1%, K -1.5%, APC -1.2%, BEXP -1.1%.
Other news: SWI -5.3% (still checking), OFC -4.5% (announces offering of 6,500,000 common shares), TRS -4.2% (announces sale of 3,000,000 shares of common stock by stockholder), LAZ -3.8% (announces certain shareholders have agreed to sell 3 mln of their shares of Lazard Ltd Class A common stock in an underwritten public offering), BBVA -1.6% (GE Capital sells Garanti stake to BBVA), NUVA -0.6% (weakness attributed to tier 1 firm downgrade).
Analyst comments: MVIS -15.0% (downgraded to Hold from Buy at Stifel Nicolaus), PTEN -1.9% (downgraded to Sell from Neutral at Goldman).
Gapping up
In reaction to strong earnings/guidance: BPI +14.8%, RDN +13.4%, NAVR +10.0%, SKH +9.4% (ticking higher; also upgraded to Buy from Hold at Citigroup), MPEL +7.5% (light volume), SHOO +7.5%, CGNX +6.8%, NTRI +6.8%, NVMI +6.1%, IVAC +5.3%, DEPO +4.9%, LF +4.5%, IOSP +3.6% (light volume), MA +3.3%, PRGO +3.0%, BP +1.5%, TEVA +1.5%.
M&A news: TEAM +16.1% (light volume; TechTeam to merge with Stefanini IT Solutions affiliate for $8.35 per share).
Select financial related names showing strength: NBG +2.9%, UBS +2.8%, ING +2.6%, CS +2.1%, CS +2.0%, DB +1.8%, HBC +1.2%, STD +1.1%.
Select mortgage insurer names ticking higher following RDN results: MTG +5.9%, PMI +4.4%, MBI +0.8%.
Select metals/mining stocks trading higher: MT +2.1%, BHP +1.9%, BBL +1.7%, SLW +1.7%, RIO +1.5%, VALE +1.4%, NEM +1.2%, FCX +1.2%, AUY +1.1%, ABX +1.0%.
Select oil/gas related names showing strength: TOT +2.6%, STO +2.3%, E +2.1%, RIG +1.3%, RDS.A +1.1%.
Select European drug names trading higher: SNY +1.6%, NVS +1.2%, AZN +1.0%.
Other news: IRWD +12.6% and FRX +3.7% (Forest Labs and Ironwood announce positive Linaclotide results from Second Phase 3 trial in patients with Irritable Bowel Syndrome with Constipation), RGN +8.4% (ticking higher, Reports Positive Results of Preclinical Dry Eye Study), HNSN +13.2% (Hansen Medical announces that it has received unconditional Investigational Device Exemption approval from the FDA), LGND +8.1% (receives approval for Revolade in Japan ), VTRO +3.9% (continued strength), RFMD +1.7% and AGN +1.1% (Cramer makes positive comments on MadMoney), NXG +1.4% (discovers high grade mineralization in a previously untested area at its Stawell Gold Mine), RRD +1.3% (Awarded Multi-Year Catalog Production Agreement by Swanson Health Products).
Analyst comments: ENDP +1.4% (upgraded to Strong Buy from Buy at Duncan Williams), MRVL +1.3% (upgraded to Positive from Neutral at Susquehanna).